

PRESS RELEASE

29 March 2022

Genflow Biosciences Plc
("Genflow" or "the Company")

New Research Collaboration with the University of Rochester's Aging Research Center
Opportunity to Demonstrate the Reversal of the Aging Process in Liver Tissue

Genflow (LSE: GENF) is pleased to announce it has commenced a scientific research collaboration with the University of Rochester's Aging Research Center (RoAR). This collaboration will initially research the potential of Sirtuin-6 ("SIRT6") in reversing the aging process in liver tissue. This is the first step towards a true rejuvenation gene therapy across a range of tissues.

RoAR is one of the world's pre-eminent age research facilities. The collaborative research will be spearheaded by a member of the Company's scientific advisory board, Dr Vera Gorbunova, who is also a co-director of RoAR and an internationally acclaimed leading scientist in the areas of DNA repair and the aging process. Dr Gorbunova has received awards from The Ellison Medical Foundation, The Glenn Foundation, American Federation for Aging Research and the National Institute of Health.

The SIRT6 gene variant found in centenarians (people aged more than 100 years old) has previously demonstrated significant capabilities in epigenetic tissue rejuvenation. The ability of SIRT6 to act on the rejuvenation of cells is a significant finding, indicative of the SIRT6 gene mutation's potential to not just halt the aging process, but to reverse it.

While the research collaboration will initially explore the ability of gene therapy for the rejuvenation of the liver, it could have significant implications beyond liver tissue and may indicate SIRT6's potential across a range of tissue rejuvenation and, for longevity research, more widely. The data obtained from the collaboration will support the pre-clinical trials Genflow is undertaking and will expedite its development of gene therapies.

Genflow is a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age. It is the first longevity biotechnology company to list in Europe and seeks to be a reference company in the European longevity sector.

In the near term, this distinguished collaboration will provide the Company with a deeper presence in, and exposure to, the US. The US longevity sector has gained enormous attention and traction in recent years. High profile Ultra Net Worths have a keen interest in this area and prominent deals in the sector attracted investment capital of over \$3bn last year.

Dr Eric Leire, Founder and CEO of Genflow, said: "We are privileged to be collaborating with the Rochester Aging Research Center (RoAR) to accelerate and enable bringing a novel gene therapy for not only improving healthy aging to the clinic and patients, but also offering the opportunity of epigenetic tissue rejuvenation. The preliminary data from the Gorbunova and Seluanov Laboratory at the University of Rochester is a promising indication of the centenarian SIRT6 gene mutation's significant capabilities in the longevity field.

"We now have the opportunity to demonstrate that SIRT6 can go beyond halting or stopping the aging process but can also reverse it. In effect, we seek to demonstrate that you can take an old liver and make it young again – this is the essence of the epigenetic tissue rejuvenation we are exploring, and it has the potential to be the basis of a revolutionary gene therapy."

For further information please contact:

Genflow Biosciences Plc	
Dr Eric Leire Chief Executive	via Tancredi +44 203 434 2330
Clear Capital Markets Ltd	
Corporate Broker Jonathan Critchley Keith Swann	+44 203 869 6086 +44 203 897 0981
Tancredi Intelligent Communication Media Relations	
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio	+44 7957 549 906 +44 7449 226 720 +44 7838 029 970 genflowbio@tancredigroup.com

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus (“AAV”) vectors to deliver copies of the Sirtuin-6 (“SIRT6”) gene variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

About Rochester Aging Research (RoAR) Center and The University of Rochester Aging Institute

The Rochester Aging Research (RoAR) Center’s mission is to promote vitality in aging by transforming care and communities through discovery, learning, collaboration and innovation.

The University of Rochester Aging Institute (URAI) is a university-wide initiative that integrates existing aging-related strengths and expertise, spanning a myriad of departments, schools and research centers across campuses, including research, patient care, education and community outreach.

To learn more visit: www.urmc.rochester.edu/university-of-rochester-aging-institute/

-Ends-